主要股东
注:以下部分股东代表特定权益共同体,直接或间接持有上市公司股份
| 序号 | 股东名称 | 是否机构 | 持股数(股) | 持股比例 | 持股变动数(股) | 持股数变动比例 | 投票权比例 |
|---|---|---|---|---|---|---|---|
| 1 | Roivant Sciences Ltd. | 是 | 3884.75万 | 21.60% |
|
|
-- |
| 2 | David Salanic,Joseph Kaplan | 否 | 1319.71万 | 7.30% | 新增 | 新增 | -- |
| 3 | 贝莱德集团公司 | 是 | 1039.03万 | 5.80% | 新增 | 新增 | -- |
| 4 | Two Seas Capital LP | 是 | 904.19万 | 5.00% | 新增 | 新增 | -- |
内部人交易
| 日期 | 股东名称 | 变动股数(万股) | 交易后持股数量(万股) | 交易价格 | 是否直接持有 | 内部人类型 |
|---|---|---|---|---|---|---|
| 2025-02-14 | HASTINGS DAVID C |
|
24.98 | 0.00 | 是 | Chief Financial Officer |
| 2025-02-14 | Naftzger J. Christopher |
|
14.05 | 0.00 | 是 | General Counsel and CCO |
| 2025-02-14 | McElhaugh Michael J. |
|
165.80 | 0.00 | 是 | Interim President & CEO |
| 2025-02-14 | Sims Karen |
|
15.55 | 0.00 | 是 | Chief Medical Officer |
| 2025-02-04 | HASTINGS DAVID C |
|
15.97 | 3.28 | 是 | Chief Financial Officer |
| 2025-02-04 | Sims Karen |
|
10.62 | 3.28 | 是 | Chief Medical Officer |
| 2025-02-04 | Naftzger J. Christopher |
|
8.62 | 3.28 | 是 | General Counsel and CCO |
| 2025-02-04 | McElhaugh Michael J. |
|
148.10 | 3.28 | 是 | Interim President & CEO |
| 2024-08-14 | MANCHESTER KEITH S |
|
4.61 | 3.69 | 是 | -- |
| 2024-08-14 | MANCHESTER KEITH S |
|
5.49 | 0.56 | 是 | -- |
| 2024-02-01 | HASTINGS DAVID C |
|
18.19 | 2.31 | 是 | Chief Financial Officer |
| 2024-02-01 | HASTINGS DAVID C |
|
19.15 | 0.00 | 是 | Chief Financial Officer |
| 2024-02-01 | Sofia Michael J. |
|
149.51 | 0.00 | 是 | Chief Scientific Officer |
| 2024-02-01 | Sofia Michael J. |
|
148.51 | 2.31 | 是 | Chief Scientific Officer |
| 2024-02-01 | Sims Karen |
|
12.99 | 0.00 | 是 | Chief Medical Officer |
| 2024-02-01 | McElhaugh Michael J. |
|
151.50 | 0.00 | 是 | Interim President & CEO |
| 2024-02-01 | McElhaugh Michael J. |
|
150.48 | 2.31 | 是 | Interim President & CEO |
| 2024-02-01 | Sims Karen |
|
12.55 | 2.31 | 是 | Chief Medical Officer |
| 2024-02-01 | Naftzger J. Christopher |
|
9.51 | 0.00 | 是 | General Counsel and CCO |